Drug Search Results
More Filters [+]

Saracatinib

Alternative Names: saracatinib, azd0530, saracatinab
Latest Update: 2024-07-30
Latest Update Note: News Article

Product Description

Mechanisms of Action: SRC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Saracatinib

Countries in Clinic: Germany, Netherlands, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Fibrodysplasia Ossificans Progressiva|Idiopathic Pulmonary Fibrosis|Myositis Ossificans

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STOPFOP

P2

Recruiting

Fibrodysplasia Ossificans Progressiva|Myositis Ossificans

2025-05-06

STOP-IPF

P2

Active, not recruiting

Idiopathic Pulmonary Fibrosis

2024-09-15

STOPFOP

P2

Active, not recruiting

Unknown

2022-06-08

Recent News Events